Kidney cancer, also called renal cancer, is cancer that starts in kidney cells, most commonly renal cell carcinoma. It may invade nearby tissues and spread to distant organs if not detected and treated early.
Two innovative CAR-T approaches show promise against solid tumors in preclinical studies. An in vivo gene editing system generates CAR-T cells directly in the body, while HLA-independent T cell receptors target CD70 across various tumor types. Both methods have demonstrated tumor clearance in mouse models, potentially expanding cell therapy applications beyond blood cancers.
The ProSense Cryoablation System achieved an 83.9% recurrence-free rate in kidney cancer patients after 4 years in the ICESECRET trial. The system treats small renal masses up to 5 cm and is approved in multiple global markets. Detailed results will be presented at the European Conference on Interventional Oncology in April 2026.
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
The global next generation drug conjugates market is projected to grow from $3.9 billion in 2026 to $10.9 billion by 2033 at 15.3% CAGR, while the radionuclide drug conjugate segment is forecast to reach $20.22 billion by 2032 at 9.6% CAGR.
Phase III trial demonstrates belzutifan plus lenvatinib significantly improved progression-free survival versus cabozantinib in previously treated renal cell carcinoma patients, while neoadjuvant studies show promise for locally advanced disease.
New research demonstrates that physical activity after cancer diagnosis reduces mortality risk in less common cancers and enhances circadian clock function in tumor tissue, supporting exercise as a therapeutic intervention.
University of Alberta researchers identified GlpG protease as a new drug target for treating antibiotic-resistant E. coli, which causes 250,000 UTI deaths annually. Inhibiting the protease prevented bacterial adhesion and biofilm formation in laboratory tests.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07410676 |
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT07401875 |
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) |
RECRUITING | PHASE1 |
| NCT07397611 |
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC |
RECRUITING | PHASE2 |
| NCT07327489 |
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies |
RECRUITING | |
| NCT07297160 |
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07284953 |
A Novel Haemostatic Agent for Robotic Partial Nephrectomy |
WITHDRAWN | NA |
| NCT07243067 |
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer |
NOT_YET_RECRUITING | |
| NCT07123090 |
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma |
RECRUITING | PHASE2 |
| NCT07065825 |
Tumor Rupture During Robotic Partial Nephrectomy |
NOT_YET_RECRUITING | |
| NCT06965192 |
Designing Visual Tools to Enhance Cancer Surgeon Decision-making |
RECRUITING | NA |
